Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy

Antisense oligonucleotides (AONs) used to reframe dystrophin mRNA transcripts for Duchenne muscular dystrophy (DMD) patients are tested in clinical trials. Here, AONs are administered subcutaneously and intravenously, while the less invasive oral route would be preferred. Oral delivery of encapsulat...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Maaike van Putten, Courtney Young, Sjoerd van den Berg, Amanda Pronk, Margriet Hulsker, Tatyana G Karnaoukh, Rick Vermue, Ko Willems van Dijk, Sjef de Kimpe, Annemieke Aartsma-Rus
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2014-01-01
Edice:	Molecular Therapy: Nucleic Acids
Témata:	antisense oligonucleotides bioavailability Duchenne muscular dystrophy dystrophin oral administration
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S216225311630350X
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!